Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy

P. Kletting, B. Muller, B. Erentok, J. Schmaljohann, F.F. Behrendt, S.N. Reske, F.M. Mottaghy, G. Glatting

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)

Abstract

PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pretherapeutic and therapeutic biodistribution. In this study the authors investigate if this assumption is justified in sst2-receptor targeting peptide therapy, as unequal amounts of peptide and different peptides for pretherapeutic measurements and therapy are commonly used. METHODS: Physiologically based pharmacokinetic models were developed. Gamma camera and serum measurements of ten patients with metastasizing neuroendocrine tumors were conducted using (111)In-DTPAOC. The most suitable model was selected using the corrected Akaike information criterion. Based on that model and the estimated individual parameters, predicted and measured (90)Y-DOTATATE excretions during therapy were compared. The residence times for the pretherapeutic (measured) and therapeutic scenarios (simulated) were calculated. RESULTS: Predicted and measured therapeutic excretion differed in three patients by 10%, 31%, and 7%. The measured pretherapeutic and therapeutic excretion differed by 53%, 56%, and 52%. The simulated therapeutic residence times of kidney and tumor were 3.1 +/- 0.6 and 2.5 +/- 1.2 fold higher than the measured pretherapeutic ones. CONCLUSIONS: To avoid the introduction of unnecessary inaccuracy in dosimetry, using the same substance along with the same amount for pretherapeutic measurements and therapy is recommended.
Original languageEnglish
Pages (from-to)5708-5717
Number of pages10
JournalMedical Physics
Volume39
Issue number9
DOIs
Publication statusPublished - Sep 2012

Keywords

  • PBPK modeling
  • PRRT
  • Y-90-DOTATATE
  • dosimetry
  • therapy planning
  • AKAIKE INFORMATION CRITERION
  • PHARMACOKINETIC MODEL
  • SOMATOSTATIN ANALOG
  • ANTI-CD45 ANTIBODY
  • MOLECULAR-SIZE
  • TUMOR UPTAKE
  • DOSIMETRY
  • BIODISTRIBUTION
  • RADIOIMMUNOTHERAPY
  • AFFINITY

Cite this

Kletting, P., Muller, B., Erentok, B., Schmaljohann, J., Behrendt, F. F., Reske, S. N., ... Glatting, G. (2012). Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Medical Physics, 39(9), 5708-5717. https://doi.org/10.1118/1.4747266
Kletting, P. ; Muller, B. ; Erentok, B. ; Schmaljohann, J. ; Behrendt, F.F. ; Reske, S.N. ; Mottaghy, F.M. ; Glatting, G. / Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. In: Medical Physics. 2012 ; Vol. 39, No. 9. pp. 5708-5717.
@article{07bef126ec6d41a6b1f52ac9feebd793,
title = "Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy",
abstract = "PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pretherapeutic and therapeutic biodistribution. In this study the authors investigate if this assumption is justified in sst2-receptor targeting peptide therapy, as unequal amounts of peptide and different peptides for pretherapeutic measurements and therapy are commonly used. METHODS: Physiologically based pharmacokinetic models were developed. Gamma camera and serum measurements of ten patients with metastasizing neuroendocrine tumors were conducted using (111)In-DTPAOC. The most suitable model was selected using the corrected Akaike information criterion. Based on that model and the estimated individual parameters, predicted and measured (90)Y-DOTATATE excretions during therapy were compared. The residence times for the pretherapeutic (measured) and therapeutic scenarios (simulated) were calculated. RESULTS: Predicted and measured therapeutic excretion differed in three patients by 10{\%}, 31{\%}, and 7{\%}. The measured pretherapeutic and therapeutic excretion differed by 53{\%}, 56{\%}, and 52{\%}. The simulated therapeutic residence times of kidney and tumor were 3.1 +/- 0.6 and 2.5 +/- 1.2 fold higher than the measured pretherapeutic ones. CONCLUSIONS: To avoid the introduction of unnecessary inaccuracy in dosimetry, using the same substance along with the same amount for pretherapeutic measurements and therapy is recommended.",
keywords = "PBPK modeling, PRRT, Y-90-DOTATATE, dosimetry, therapy planning, AKAIKE INFORMATION CRITERION, PHARMACOKINETIC MODEL, SOMATOSTATIN ANALOG, ANTI-CD45 ANTIBODY, MOLECULAR-SIZE, TUMOR UPTAKE, DOSIMETRY, BIODISTRIBUTION, RADIOIMMUNOTHERAPY, AFFINITY",
author = "P. Kletting and B. Muller and B. Erentok and J. Schmaljohann and F.F. Behrendt and S.N. Reske and F.M. Mottaghy and G. Glatting",
year = "2012",
month = "9",
doi = "10.1118/1.4747266",
language = "English",
volume = "39",
pages = "5708--5717",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "Wiley",
number = "9",

}

Kletting, P, Muller, B, Erentok, B, Schmaljohann, J, Behrendt, FF, Reske, SN, Mottaghy, FM & Glatting, G 2012, 'Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy', Medical Physics, vol. 39, no. 9, pp. 5708-5717. https://doi.org/10.1118/1.4747266

Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. / Kletting, P.; Muller, B.; Erentok, B.; Schmaljohann, J.; Behrendt, F.F.; Reske, S.N.; Mottaghy, F.M.; Glatting, G.

In: Medical Physics, Vol. 39, No. 9, 09.2012, p. 5708-5717.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy

AU - Kletting, P.

AU - Muller, B.

AU - Erentok, B.

AU - Schmaljohann, J.

AU - Behrendt, F.F.

AU - Reske, S.N.

AU - Mottaghy, F.M.

AU - Glatting, G.

PY - 2012/9

Y1 - 2012/9

N2 - PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pretherapeutic and therapeutic biodistribution. In this study the authors investigate if this assumption is justified in sst2-receptor targeting peptide therapy, as unequal amounts of peptide and different peptides for pretherapeutic measurements and therapy are commonly used. METHODS: Physiologically based pharmacokinetic models were developed. Gamma camera and serum measurements of ten patients with metastasizing neuroendocrine tumors were conducted using (111)In-DTPAOC. The most suitable model was selected using the corrected Akaike information criterion. Based on that model and the estimated individual parameters, predicted and measured (90)Y-DOTATATE excretions during therapy were compared. The residence times for the pretherapeutic (measured) and therapeutic scenarios (simulated) were calculated. RESULTS: Predicted and measured therapeutic excretion differed in three patients by 10%, 31%, and 7%. The measured pretherapeutic and therapeutic excretion differed by 53%, 56%, and 52%. The simulated therapeutic residence times of kidney and tumor were 3.1 +/- 0.6 and 2.5 +/- 1.2 fold higher than the measured pretherapeutic ones. CONCLUSIONS: To avoid the introduction of unnecessary inaccuracy in dosimetry, using the same substance along with the same amount for pretherapeutic measurements and therapy is recommended.

AB - PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pretherapeutic and therapeutic biodistribution. In this study the authors investigate if this assumption is justified in sst2-receptor targeting peptide therapy, as unequal amounts of peptide and different peptides for pretherapeutic measurements and therapy are commonly used. METHODS: Physiologically based pharmacokinetic models were developed. Gamma camera and serum measurements of ten patients with metastasizing neuroendocrine tumors were conducted using (111)In-DTPAOC. The most suitable model was selected using the corrected Akaike information criterion. Based on that model and the estimated individual parameters, predicted and measured (90)Y-DOTATATE excretions during therapy were compared. The residence times for the pretherapeutic (measured) and therapeutic scenarios (simulated) were calculated. RESULTS: Predicted and measured therapeutic excretion differed in three patients by 10%, 31%, and 7%. The measured pretherapeutic and therapeutic excretion differed by 53%, 56%, and 52%. The simulated therapeutic residence times of kidney and tumor were 3.1 +/- 0.6 and 2.5 +/- 1.2 fold higher than the measured pretherapeutic ones. CONCLUSIONS: To avoid the introduction of unnecessary inaccuracy in dosimetry, using the same substance along with the same amount for pretherapeutic measurements and therapy is recommended.

KW - PBPK modeling

KW - PRRT

KW - Y-90-DOTATATE

KW - dosimetry

KW - therapy planning

KW - AKAIKE INFORMATION CRITERION

KW - PHARMACOKINETIC MODEL

KW - SOMATOSTATIN ANALOG

KW - ANTI-CD45 ANTIBODY

KW - MOLECULAR-SIZE

KW - TUMOR UPTAKE

KW - DOSIMETRY

KW - BIODISTRIBUTION

KW - RADIOIMMUNOTHERAPY

KW - AFFINITY

U2 - 10.1118/1.4747266

DO - 10.1118/1.4747266

M3 - Article

VL - 39

SP - 5708

EP - 5717

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 9

ER -

Kletting P, Muller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Medical Physics. 2012 Sep;39(9):5708-5717. https://doi.org/10.1118/1.4747266